Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 472 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| CT Cyllene TherapeuticsCompany profile Develops DNA medicines for severe neurogenic bladder conditions and other neurological diseases Develops DNA medicines for severe neurogenic bladder conditions and other neurological diseases | €33M | Series CSeries C+ | Biotech | France | Investors | |
| C CurifyLabsCompany profile CurifyLabs develops software and GMP-manufactured excipients for preparing personalized medicines. CurifyLabs develops software and GMP-manufactured excipients for preparing personalized medicines. | $14M | Series A | Biotech, Healthtech | Finland | Investors | |
| CT Develops treatments for serious respiratory diseases | $180M | Growth | Biotech | United States | Investors | |
| XB Xellar BiosystemsCompany profile Develops 3D human tissue models for drug discovery and testing using Organ-on-a-Chip technology Develops 3D human tissue models for drug discovery and testing using Organ-on-a-Chip technology | $50M | Series A | Biotech | United States | Investors Undisclosed | |
| LL Leyden LaboratoriesCompany profile Develops antibody-based nasal sprays intended to prevent influenza and other respiratory-virus infections. Develops antibody-based nasal sprays intended to prevent influenza and other respiratory-virus infections. | €40M | Series B | Biotech | Netherlands | Investors | |
| T TissiumCompany profile Develops biomorphic programmable polymers that repair nerves and tissue without stitches Develops biomorphic programmable polymers that repair nerves and tissue without stitches | €30M | Series D+Series C+ | Biotech, Healthtech | France | Investors | |
| OB Ollin BiosciencesCompany profile Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD | $330M | Series B | Biotech | United States | Investors | |
| AN Anodyne NanotechCompany profile Develops transdermal microneedle patches delivering GLP-1 and biologic therapeutics without injections Develops transdermal microneedle patches delivering GLP-1 and biologic therapeutics without injections | $12.6M | Series A | Biotech | United States | Investors | |
| RB RQ BioCompany profile Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients | $115M | Series A | Biotech | United Kingdom | Investors | |
| RH Rapalogix HealthCompany profile Develops prescription therapeutics and skincare products for cellular longevity and skin health Develops prescription therapeutics and skincare products for cellular longevity and skin health | $20M | Series A | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.